BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Allweiss L, Giersch K, Pirosu A, Volz T, Muench RC, Beran RK, Urban S, Javanbakht H, Fletcher SP, Lütgehetmann M, Dandri M. Therapeutic shutdown of HBV transcripts promotes reappearance of the SMC5/6 complex and silencing of the viral genome in vivo. Gut 2021:gutjnl-2020-322571. [PMID: 33509930 DOI: 10.1136/gutjnl-2020-322571] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Tavis J, Chauhan R. Silencing HBV transcription with SMC5/6: has a path been found? Gut 2021:gutjnl-2021-324144. [PMID: 33649046 DOI: 10.1136/gutjnl-2021-324144] [Reference Citation Analysis]
2 Soliman SHA, Orlacchio A, Verginelli F. Viral Manipulation of the Host Epigenome as a Driver of Virus-Induced Oncogenesis. Microorganisms 2021;9:1179. [PMID: 34070716 DOI: 10.3390/microorganisms9061179] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Mnyandu N, Limani SW, Arbuthnot P, Maepa MB. Advances in designing Adeno-associated viral vectors for development of anti-HBV gene therapeutics. Virol J 2021;18:247. [PMID: 34903258 DOI: 10.1186/s12985-021-01715-9] [Reference Citation Analysis]
4 Ye J, Chen J. Interferon and Hepatitis B: Current and Future Perspectives. Front Immunol 2021;12:733364. [PMID: 34557195 DOI: 10.3389/fimmu.2021.733364] [Reference Citation Analysis]
5 Niklasch M, Zimmermann P, Nassal M. The Hepatitis B Virus Nucleocapsid-Dynamic Compartment for Infectious Virus Production and New Antiviral Target. Biomedicines 2021;9:1577. [PMID: 34829806 DOI: 10.3390/biomedicines9111577] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Ligat G, Verrier ER, Nassal M, Baumert TF. Hepatitis B virus-host interactions and novel targets for viral cure. Curr Opin Virol 2021;49:41-51. [PMID: 34029994 DOI: 10.1016/j.coviro.2021.04.009] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Martinez MG, Boyd A, Combe E, Testoni B, Zoulim F. Covalently closed circular DNA: The ultimate therapeutic target for curing HBV infections. J Hepatol 2021;75:706-17. [PMID: 34051332 DOI: 10.1016/j.jhep.2021.05.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
8 Maepa MB, Bloom K, Ely A, Arbuthnot P. Hepatitis B virus: promising drug targets and therapeutic implications. Expert Opin Ther Targets 2021;25:451-66. [PMID: 33843412 DOI: 10.1080/14728222.2021.1915990] [Reference Citation Analysis]
9 Dybas JM, Lum KK, Kulej K, Reyes ED, Lauman R, Charman M, Purman CE, Steinbock RT, Grams N, Price AM, Mendoza L, Garcia BA, Weitzman MD. Adenovirus Remodeling of the Host Proteome and Host Factors Associated with Viral Genomes. mSystems 2021;:e0046821. [PMID: 34463575 DOI: 10.1128/mSystems.00468-21] [Reference Citation Analysis]
10 Dash PK, Gorantla S, Poluektova L, Hasan M, Waight E, Zhang C, Markovic M, Edagwa B, Machhi J, Olson KE, Wang X, Mosley RL, Kevadiya B, Gendelman HE. Humanized Mice for Infectious and Neurodegenerative disorders. Retrovirology 2021;18:13. [PMID: 34090462 DOI: 10.1186/s12977-021-00557-1] [Reference Citation Analysis]